In the recent letter from Hale and Waldmann 1 there appears to be some confusion about CE (Conformité Européenne) marking and FDA approval of the CEPRATE ® SC Stem Cell registered Concentration System. CE marking and FDA approval for medical devices are given by two independent authorities based on different criteria and have legal force only in their respective territories. This approval system is different from the system used for drugs. In order to receive the CE marking, the manufacturer must demonstrate that the device is in compliance with the Medical Device Directive. 2 In brief, the Medical Device Directive requires that the manufacturer demonstrates that the devices will not compromise the safety and health of patients and it achieves the performance intended and claimed by the manufacturer. In order to receive FDA approval, the manufacturer must demonstrate that the device is safe and provides a clinical benefit.
In Europe, the CEPRATE SC Stem Cell Selection System and the CEPRATE TCD T cell Depletion System have been granted the CE marking. The CEPRATE SC System is indicated for the positive selection of CD34 + cells (hematopoietic progenitor cells) from bone marrow or mobilized peripheral blood. Data from published studies were provided in the dossier submitted to the notified body demonstrating that positive selection of CD34 + cells using the CEPRATE SC System results in a mean 2.5 to 3 log reduction in T cells 3, 4 and/or a 2 log or greater reduction in tumor cells.
The CEPRATE TCD System is indicated for a supplementary depletion of T cells from a CD34 selected population. Data were provided demonstrating that the CEPRATE TCD System results in an additional log of T cell depletion.
In the United States, the CEPRATE SC Stem Cell Selection System is approved by the FDA for the positive selection of CD34 + cells (hematopoietic progenitor cells) from bone marrow to reduce the toxicities associated with infusion of bone marrow. 5 CellPro has submitted additional data to include an indication for the use of peripheral blood. These data demonstrate that the positive selection of PBSC results in a 3 log reduction in tumor cells. All of the labeling and literature that CellPro Incorporated provides to customers in Europe and the United States is consistent with the medical device approvals in the respective territories.
Additional studies sponsored by CellPro are in progress to confirm the clinical utility of the CEPRATE SC System for tumor cell purging in the autologous transplantation and of the CEPRATE SC and TCD Systems used in the allogeneic setting. The large number of presentations done at scientific meetings, despite the fact that neither European nor United States regulatory agencies restrict the use of approved products by clinicians, confirms the awareness of the transplant groups of the need for supplementary clinical data. 
